Is ABDOMINAL PAIN UPPER a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ABDOMINAL PAIN UPPER.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 110 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ABDOMINAL PAIN UPPER to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ABDOMINAL PAIN UPPER. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ABDOMINAL PAIN UPPER, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ABDOMINAL PAIN UPPER. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ABDOMINAL PAIN UPPER ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ABDOMINAL PAIN UPPER: 110
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ABDOMINAL PAIN UPPER is a reported side effect: 3.3043%

FDA reports of any drug causing ABDOMINAL PAIN UPPER : 49007
Average percentage for all medicated patients where ABDOMINAL PAIN UPPER is reported as a complication: 0.3071%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ABDOMINAL PAIN UPPER:

NEXIUM (3560 patients)
ASPIRIN (3503 patients)
YAZ (3439 patients)
YASMIN (3224 patients)
VIOXX (2606 patients)
LIPITOR (2056 patients)
FOSAMAX (2001 patients)
CHANTIX (1907 patients)
SEROQUEL (1845 patients)
HUMIRA (1803 patients)
BYETTA (1761 patients)
SYNTHROID (1520 patients)
PRILOSEC (1519 patients)
LISINOPRIL (1491 patients)
OMEPRAZOLE (1476 patients)
FORTEO (1376 patients)
IBUPROFEN (1261 patients)
PREDNISONE (1239 patients)
PROTONIX (1194 patients)
METFORMIN HCL (1173 patients)
LASIX (1128 patients)
XANAX (1120 patients)
ALLI (1118 patients)
SANDOSTATIN LAR (1117 patients)
CELEBREX (1094 patients)
SIMVASTATIN (1088 patients)
ATENOLOL (1076 patients)
PREVACID (1072 patients)
PLAVIX (1063 patients)
CYMBALTA (1040 patients)
NEURONTIN (981 patients)
HYDROCHLOROTHIAZIDE (952 patients)
ZOLOFT (947 patients)
CRESTOR (940 patients)
ACETAMINOPHEN (909 patients)
COUMADIN (908 patients)
AMBIEN (905 patients)
TYSABRI (901 patients)
LYRICA (897 patients)
ENBREL (879 patients)
EXJADE (877 patients)
ZOCOR (876 patients)
ALBUTEROL (875 patients)
FOLIC ACID (855 patients)
NORVASC (849 patients)
TOPROL-XL (845 patients)
SINGULAIR (839 patients)
FUROSEMIDE (832 patients)
PAXIL (814 patients)
METHOTREXATE (810 patients)
VICODIN (804 patients)
ZOMETA (801 patients)
LEVOTHYROXINE SODIUM (776 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (771 patients)
HEPARIN SODIUM INJECTION (769 patients)
PRADAXA (767 patients)
OXYCONTIN (760 patients)
REMICADE (759 patients)
DIOVAN (751 patients)
VITAMIN D (717 patients)
LEXAPRO (716 patients)
ZANTAC (683 patients)
DIGOXIN (668 patients)
PERCOCET (663 patients)
ATIVAN (656 patients)
AVONEX (650 patients)
WELLBUTRIN (647 patients)
ZOFRAN (641 patients)
POTASSIUM CHLORIDE (641 patients)
LANTUS (639 patients)
CLONAZEPAM (626 patients)
LORAZEPAM (623 patients)
PREDNISOLONE (619 patients)
KLONOPIN (616 patients)
CALCIUM (609 patients)
PROZAC (609 patients)
TYLENOL (CAPLET) (602 patients)
NIASPAN (591 patients)
ZYRTEC (590 patients)
ACCUTANE (589 patients)
GABAPENTIN (579 patients)
GLUCOPHAGE (575 patients)
ALEVE (CAPLET) (575 patients)
BONIVA (572 patients)
MULTI-VITAMIN (569 patients)
AMOXICILLIN (564 patients)
ALEVE (560 patients)
OCELLA (547 patients)
NEXAVAR (544 patients)
PREDNISONE TAB (531 patients)
MULTI-VITAMINS (524 patients)
ADVAIR DISKUS 100/50 (523 patients)
LORTAB (521 patients)
METFORMIN (512 patients)
PREMARIN (511 patients)
METOPROLOL TARTRATE (503 patients)
LEVAQUIN (501 patients)
TYLENOL (496 patients)
ALLEGRA (492 patients)
STRATTERA (488 patients)
INSULIN (486 patients)
AMLODIPINE (485 patients)
EFFEXOR (483 patients)
ZYPREXA (474 patients)
MORPHINE (472 patients)
REGLAN (470 patients)
TRAMADOL HCL (468 patients)
ALPRAZOLAM (465 patients)
AREDIA (461 patients)
CELEXA (460 patients)
WARFARIN SODIUM (459 patients)
COREG (459 patients)
TOPAMAX (458 patients)
SPIRIVA (458 patients)
ALLOPURINOL (455 patients)
NAPROXEN (454 patients)
FISH OIL (448 patients)
VICTOZA (445 patients)
MOTRIN (444 patients)
RANITIDINE (436 patients)
NITROGLYCERIN (427 patients)
ASCORBIC ACID (423 patients)
BENADRYL (422 patients)
HEPARIN SODIUM (421 patients)
GLIPIZIDE (414 patients)
AVANDIA (412 patients)
DIAZEPAM (408 patients)
OXYCODONE HCL (405 patients)
ZITHROMAX (402 patients)
LANSOPRAZOLE (401 patients)
ZETIA (397 patients)
ACTOS (395 patients)
METOPROLOL (393 patients)
RIBAVIRIN (391 patients)
AZITHROMYCIN (387 patients)
VALIUM (379 patients)
CALCIUM CARBONATE (377 patients)
FLEXERIL (375 patients)
ACIPHEX (375 patients)
ACTONEL (374 patients)
KETEK (374 patients)
PANTOPRAZOLE (369 patients)
VITAMIN B-12 (369 patients)
TRAZODONE HCL (367 patients)
SOLIRIS (367 patients)
MIRENA (365 patients)
GLYBURIDE (364 patients)
GLEEVEC (362 patients)
PROMETHAZINE (360 patients)
CLONIDINE (360 patients)
SPIRONOLACTONE (358 patients)
CIPROFLOXACIN (354 patients)
AMARYL (351 patients)
FLONASE (350 patients)
TRICOR (348 patients)
COZAAR (342 patients)
LAMICTAL (342 patients)
CLARITIN (337 patients)
RAMIPRIL (329 patients)
DEXAMETHASONE (329 patients)
HYDROCODONE (328 patients)
METOCLOPRAMIDE (326 patients)
PEPCID (323 patients)
BEXTRA (322 patients)
PHENERGAN (320 patients)
HUMALOG (317 patients)
DURAGESIC-100 (316 patients)
VITAMIN E (315 patients)
ANTIBIOTICS (314 patients)
ALTACE (313 patients)
PEGASYS (310 patients)
LEVOXYL (307 patients)
ADVIL (302 patients)
ULTRAM (301 patients)
AVELOX (297 patients)
FLUCONAZOLE (297 patients)
ZELNORM (297 patients)
DILAUDID (296 patients)
EFFEXOR XR (296 patients)
VYTORIN (296 patients)
FENTANYL (295 patients)
POTASSIUM (287 patients)
RISPERDAL (287 patients)
TASIGNA (283 patients)
FLUOROURACIL (281 patients)
AMITRIPTYLINE HCL (281 patients)
VALTREX (279 patients)
HYDROCODONE BITARTRATE (279 patients)
JANUVIA (279 patients)
COLACE (273 patients)
CEPHALEXIN (270 patients)
MORPHINE SULFATE (269 patients)
DOXYCYCLINE (268 patients)
ALL OTHER THERAPEUTIC PRODUCTS (268 patients)
ENALAPRIL MALEATE (267 patients)
XELODA (266 patients)
PEG-INTRON (265 patients)
DECADRON (264 patients)
VOLTAREN (263 patients)
DEMEROL (261 patients)
CIPRO (261 patients)
REVLIMID (260 patients)
METRONIDAZOLE (260 patients)
BETASERON (259 patients)
VITAMINS (259 patients)
MIRALAX (255 patients)
LOPRESSOR (253 patients)
IMITREX (252 patients)
LUNESTA (248 patients)
FLOMAX (247 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ABDOMINAL PAIN UPPER and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.